Sector revisions Celltrion, Inc.

Equities

End-of-day quote Korea S.E. Other stock markets 13/02/2026			5-day change	1st Jan Change
238,000.00 ^KRW	-0.21%		-0.63%	+31.49%

02-05	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)	RE
01-30	Celltrion Launches Autoimmune Drug Aptozma in Europe	MT

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	CELLTRION, INC.							23
	LONZA GROUP AG							23
	BEONE MEDICINES AG							24
	IQVIA HOLDINGS INC.							20
	REVOLUTION MEDICINES, INC.							18
	EUROFINS SCIENTIFIC SE							15
	ASCENDIS PHARMA A/S							16
	IONIS PHARMACEUTICALS, INC.							22
	MEDPACE HOLDINGS, INC.							12
	QIAGEN N.V.							15
	ABIVAX							5
	TEMPUS AI, INC.							13
	BIO-TECHNE CORPORATION							12
	PRAXIS PRECISION MEDICINES, INC.							16
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.							15
	PHARMARON BEIJING CO., LTD.							13
	HANGZHOU TIGERMED CONSULTING CO., LTD							11
	KYMERA THERAPEUTICS, INC.							21
	ICON PUBLIC LIMITED COMPANY							14
	Average							16
	Weighted average by Cap.							19